Department of Nuclear Medicine, PET Center, Policlinico Sant'Orsola Malpighi, Bologna University, Bologna, Italy.
Eur J Radiol. 2011 Apr;78(1):12-20. doi: 10.1016/j.ejrad.2009.12.035. Epub 2010 Feb 8.
To review the published data in literature on patients affected by gynaecological malignancies to establish the role of (18)F-FDG positron emission tomography (PET) and PET/CT in comparison to conventional imaging (CI).
All papers specifically addressed to the role of (18)F-FDG PET and PET/CT in gynaecological malignancies published on PubMed/Medline, in abstracts from the principal international congresses, in the guidelines from national Societies that had appeared in literature until November 2009 were considered for the purpose of the present study.
The use of (18)F-FDG PET, and even more of (18)F-FDG PET/CT, is increasing in the follow up of patients with gynaecologic malignancies and suspected recurrent disease: there is evidence in the literature that (18)F-FDG PET/CT has a higher sensitivity than CI in depicting occult metastatic spread. An interesting issue is represented by patients with ovarian cancer with an increase of the specific biomarker, CA-125, and negative/inconclusive findings at CI. The use of (18)F-FDG PET in differential diagnosis and staging is more controversial, but there is some evidence that a baseline PET examination performed before commencing therapy, for staging purpose, is also useful to evaluate the response to chemoradiation treatment. In several papers it has been suggested a relevant role of (18)F-FDG PET/CT in evaluating the entity of response to treatment and therefore to plan the subsequent therapeutic strategy.
回顾文献中发表的妇科恶性肿瘤患者的数据，以确定（18）F-FDG 正电子发射断层扫描（PET）和 PET/CT 与常规成像（CI）相比的作用。
本研究纳入了专门针对妇科恶性肿瘤中（18）F-FDG PET 和 PET/CT 作用的在 PubMed/Medline 上发表的所有论文、主要国际大会摘要以及在 2009 年 11 月之前发表的国家学会指南，以评估其作用。
（18）F-FDG PET 的使用，甚至更多的（18）F-FDG PET/CT 的使用，在妇科恶性肿瘤患者的随访中以及怀疑复发性疾病中正在增加：文献中有证据表明（18）F-FDG PET/CT 在描绘隐匿性转移扩散方面比 CI 具有更高的敏感性。一个有趣的问题是卵巢癌患者的特定生物标志物 CA-125 升高，而 CI 检查阴性/不确定。（18）F-FDG PET 在鉴别诊断和分期中的应用更具争议性，但有一些证据表明，在开始治疗前进行基线 PET 检查（分期目的）对于评估放化疗治疗的反应也是有用的。在一些论文中，已经提出（18）F-FDG PET/CT 在评估治疗反应的实体以及因此规划后续治疗策略方面具有重要作用。
